Search - tctmd.com

Displaying 41 - 60 of 178

Sort: Relevancy | Date

News Daily News

ACS After TAVR a Unique Condition With Poor Prognosis

Todd Neale

February 05, 2020

News Daily News

Optimal Implantation Depth With Self-Expanding TAVR? Success May Prove Elusive

Yael L. Maxwell

December 19, 2019

News Conference News AHA 2019

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Yael L. Maxwell

November 18, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

News Daily News

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

Yael L. Maxwell

August 20, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Industry News

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

August 16, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

Presentation TVT 2019

Updates From the CoreValve and EVOLUT R Aortic VIV Registries

Presenter: Jeffrey Popma

June 13, 2019

News Conference News EuroPCR 2019

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Michael O'Riordan

May 29, 2019

CHOICE: Better Hemodynamics, Less Structural Deterioration with CoreValve

News Conference News EuroPCR 2019

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Michael O'Riordan

May 24, 2019

News Conference News EuroPCR 2019

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

Michael O'Riordan

May 22, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Daily News

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Yael L. Maxwell

March 01, 2019

News Daily News

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

Shelley Wood

February 19, 2019

News Daily News

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

Todd Neale

November 20, 2018

Advertisement

ACS After TAVR a Unique Condition With Poor Prognosis

Optimal Implantation Depth With Self-Expanding TAVR? Success May Prove Elusive

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Sapien 3 Valve Approved in Europe for Low-Risk Patients

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Expert Consensus Gives Initial Guidance on Post-TAVR Conduction Disturbances

FDA Expands TAVR Indication to Low-Risk Patients

Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Updates From the CoreValve and EVOLUT R Aortic VIV Registries

Allegra TAVR System Feasible for Treating Degenerated Surgical Valves

Self-Expanding vs Balloon-Expandable TAVR? Some Insights From CHOICE

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content